Beam Therapeutics Inc
BEAMHealthcare|Biotechnology|USA
$24.07
-0.17 (-0.68%)
Tangible Book
$12.17
About
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Stock Price
+47.2%(1Y)
Pipeline Summary
14 total trials6
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 7Active: 5Completed: 2
Active Trials (12)
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
NCT06735755Glycogen Storage Disease Type Ia
Phase 1Phase 2Recruiting
Enrollment: 36 participants
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
NCT06934382T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Phase 1Recruiting
Enrollment: 33 participants
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT05885464Lymphoblastic Lymphoma
Phase 1Phase 2Active
Enrollment: 5 participants
This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
NCT07304791Healthy Subjects
Phase 1Recruiting
Enrollment: 30 participants
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877Alpha 1-Antitrypsin Deficiency
Phase 1Phase 2Recruiting
Enrollment: 106 participants
BioScore
6.4/10
Watchlist
Ownership
Recent Insider Trades
Evans John M.SELL
2026-04-0130,078 shares @ $24.58
Simon AmySELL
2026-04-016,700 shares @ $24.58
Cavanagh Bethany JSELL
2026-04-013,242 shares @ $24.58
Bellon ChristineSELL
2026-04-015,956 shares @ $24.58
Ciaramella GiuseppeSELL
2026-04-0111,810 shares @ $24.58
Recent News
2026-04-01 22:00:02
2026-04-01 21:50:36
2026-03-26 16:02:29
2026-03-25 17:25:19
2026-03-25 12:58:54
Data last updated: Apr 7, 2026, 02:30 PM